BAGCHI LAW ASSISTS TRIANGLE INSIGHTS GROUP IN ITS SALE TO TRIALCARD
MORRISVILLE, NC – TrialCard Incorporated, a full-service life sciences company, announced the acquisition of Triangle Insights Group. With this transaction, TrialCard adds a team of experienced professionals who will help continue to provide the highest levels of service. “The addition of Triangle Insights Group to the TrialCard platform is a huge win for the life sciences industry and patients in general,” said Scott Dulitz, President and Chief Strategy Officer at TrialCard. “Commercialization and operational considerations are becoming increasingly important during the early pre-approval stages of a product’s lifecycle. Our blended team of experts will be well-positioned to provide both the strategic insights and executional excellence to successfully launch and commercialize new products.”
Having worked with Triangle Insights Group since its inception, Bagchi Law is pleased to have assisted Triangle Insights Group in connection with its acquisition. “Over the last nine years, we have been delighted to work with Triangle Insights Group’s founders in the launch, growth, and ultimate sale of their dynamic services business. We enjoy helping our clients to navigate the unpredictable waters of an acquisition from beginning to end,” said Neil Bagchi, Managing Attorney at Bagchi Law.
Triangle Insights Group offers a full suite of consulting services, including R&D and portfolio strategy, new product planning and commercialization support, and extensive pricing and market access expertise and insights. Headquartered in Durham, North Carolina, with offices in New York City and San Francisco, Triangle Insights Group’s 50+ consultants combine deep knowledge of the life sciences industry across therapeutic areas and functional groups, with a dedication to creativity and strong critical thinking. Recommendations from Triangle Insights Group are original, relevant to the evolving industry landscape, and supported by rigorous analytics. The company, founded in 2013, supports clients in the biopharmaceutical, diagnostics, and medical device industries, with experience in every therapeutic area and more than 150 indications. TrialCard is pleased to announce that all TIG partners and employees will be retained by TrialCard post-acquisition. The deal marks TrialCard’s seventh acquisition since entering a partnership with Odyssey Investment Partners, LLC in November 2017.
About Bagchi Law
Bagchi Law is a team of highly skilled attorneys and professionals who work together, combining 100 years of experience, expertise, and industry knowledge. We approach your legal and business needs from every angle while assessing risks and advising on issues that could impact your organization’s growth for years to come. Our team’s diverse background and experience ensure that our clients receive the highest level of care and counsel. For more information about Bagchi Law, please visit www.bagchilaw.com.
About TrialCard
TrialCard Incorporated is a full-service life sciences commercialization company that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial supply management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization support for more than 400 life science customers and has connected over 36 million patients with more than $22 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina. For more information about TrialCard, please visit www.trialcard.com.
About Triangle Insights Group
Triangle Insights Group is a premier strategy consulting firm providing guidance on critical business issues to life science industry leaders. The firm’s approach combines deep industry knowledge with strong analytical rigor to drive strategic decision-making across client domains. Triangle’s expertise encompasses key therapeutic areas (oncology, CNS, cell, and gene therapy) and relevant industry disciplines (pricing and market access, new product planning, and commercial strategy). For more information, visit www.triangleinsightsgroup.com.
Related
For international business owners and investors in 2025, no word has caused as much headache as the word “tariffs.” The concept of both raising money and protecting local industry by taxing imports is not…
>>The Small Business Investment Act of 2025 makes sweeping changes to Qualified Small Business Stock (QSBS). Effective July 5, 2025, these reforms are designed to make QSBS even more attractive…
>>Why Growing Companies Choose Fractional CISOs: An Interview with Stacey Robinson of GP Tech Advisors
In today’s digital landscape, growing companies face mounting pressure to demonstrate cybersecurity maturity. Whether it’s to win deals, attract investment, or pass audits, the need for robust security leadership is…
>>Forming a new business is a detailed undertaking–there is a lot to consider; a great many pieces to the puzzle. Some choices you make can be changed later with relative…
>>International entrepreneurs and investors have increasingly turned to U.S. markets. According to the U.S. Treasury Department, foreign holdings of U.S. securities reached $31.3 trillion as of June 2024, including $17 trillion in U.S.…
>>Artificial intelligence (“AI”) is everywhere, and it shows no signs of slowing down. Global investment in AI technologies continues to soar; in fact, funding for generative AI startups surged to…
>>Contact Us
Let's challenge the default together